Su H Irene, Lacchetti Christina, Letourneau Joseph, Partridge Ann H, Qamar Rubina, Quinn Gwendolyn P, Reinecke Joyce, Smith James F, Tesch Megan, Wallace W Hamish, Wang Erica T, Loren Alison W
University of California, San Diego, San Diego, CA.
American Society of Clinical Oncology, Alexandria, VA.
J Clin Oncol. 2025 Apr 20;43(12):1488-1515. doi: 10.1200/JCO-24-02782. Epub 2025 Mar 19.
To provide updated fertility preservation (FP) recommendations for people with cancer.
A multidisciplinary Expert Panel convened and updated the systematic review.
One hundred sixty-six studies comprise the evidence base.
People with cancer should be evaluated for and counseled about reproductive risks at diagnosis and during survivorship. Patients interested in or uncertain about FP should be referred to reproductive specialists. FP approaches should be discussed before cancer-directed therapy. Sperm cryopreservation should be offered to males before cancer-directed treatment, with testicular sperm extraction if unable to provide semen samples. Testicular tissue cryopreservation in prepubertal males is experimental and should be offered only in a clinical trial. Males should be advised of potentially higher genetic damage risks in sperm collected soon after cancer-directed therapy initiation and completion. For females, established FP methods should be offered, including embryo, oocyte, and ovarian tissue cryopreservation (OTC), ovarian transposition, and conservative gynecologic surgery. In vitro maturation of oocytes may be offered as an emerging method. Post-treatment FP may be offered to people who did not undergo pretreatment FP or cryopreserve enough oocytes or embryos. Gonadotropin-releasing hormone agonist (GnRHa) should not be used in place of established FP methods but may be offered as an adjunct to females with breast cancer. For patients with oncologic emergencies requiring urgent oncologic therapy, GnRHa may be offered for menstrual suppression. Established FP methods in children who have begun puberty should be offered with patient assent and parent/guardian consent. The only established method for prepubertal females is OTC. Oncology teams should ensure prompt access to a multidisciplinary FP team. Clinicians should advocate for comprehensive FP services coverage and help patients access benefits.Additional information is available at www.asco.org/survivorship-guidelines.
为癌症患者提供最新的生育力保存(FP)建议。
一个多学科专家小组召开会议并更新了系统评价。
166项研究构成了证据基础。
癌症患者在确诊时及生存期间应接受生殖风险评估并得到相关咨询。对FP感兴趣或不确定的患者应转诊至生殖专家处。应在进行癌症导向治疗前讨论FP方法。应在男性进行癌症导向治疗前提供精子冷冻保存,若无法提供精液样本则进行睾丸精子提取。青春期前男性的睾丸组织冷冻保存是实验性的,仅应在临床试验中提供。应告知男性在癌症导向治疗开始和结束后不久采集的精子中可能存在更高的遗传损伤风险。对于女性,应提供已确立可行的FP方法包括胚胎、卵母细胞和卵巢组织冷冻保存(OTC)、卵巢移位和保守性妇科手术。卵母细胞的体外成熟可作为一种新兴方法提供。对于未进行预处理FP或未冷冻保存足够卵母细胞或胚胎的患者可提供治疗后FP。促性腺激素释放激素激动剂(GnRHa)不应替代已确立可行的FP方法,但可作为乳腺癌女性的辅助治疗方法提供。对于需要紧急肿瘤治疗的肿瘤急症患者,可提供GnRHa用于月经抑制。对于已开始青春期的儿童,应在患者同意且父母/监护人同意的情况下提供已确立可行的FP方法。青春期前女性唯一已确立可行的方法是OTC。肿瘤学团队应确保能迅速联系到多学科FP团队。临床医生应倡导全面覆盖FP服务并帮助患者获得相关福利。更多信息可在www.asco.org/survivorship-guidelines获取。